EC-104 eye implant for diabetic macular edema
Part of Eyes & vision clinical trials.
This early-phase trial tests a new implant (EC-104) that goes inside the eye to treat diabetic macular edema (DME), a condition that causes blurry vision from fluid buildup. The implant slowly releases medicine over time, and the study will see if it is safe and helpful for people with DME.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You have diabetic macular edema (DME) from diabetes (type 1 or type 2)
- Your vision in the study eye is between 20/40 and 20/400 on the eye chart
- You cannot have glaucoma or high eye pressure that needs treatment
- You cannot have had a steroid injection in the eye that caused very high eye pressure (over 25 mm Hg)
- You cannot have active new blood vessels growing in the back of the eye (proliferative diabetic retinopathy) that are bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.